Alnylam Pharmaceuticals, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Alnylam Pharmaceuticals, Inc. (NASDAQGS: ALNY) securities between February 15, 2018 and September 12, 2018.
According to the Alnylam lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.
“Alnylam Pharmaceuticals, Inc.”
If you suffered a loss in Alnylam you have until November 26, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.